Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 2, 1999, Pages 130-134

  Brillanti, S ^a   Foli, M ^a   Di Tomaso, M ^a   Gramantieri, L ^a   Masci, C ^a   Bolondi, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Amantadine; Liver; Response; Retreatment; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALANINE TRANSAMINASE; AMANTADINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 0032904754     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Davis GL, Baiart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant Interferon alfara multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant Interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebocontrolled trial. N Engl J Med 1989;321:1506-10.
3. Marcellin P, Boyer N, Giostra E, Degott C, Couroucè AM, Degos F, Copperè H, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
4. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
5. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Baiart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-40.
6. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
7. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon-alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
8. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995;23(Suppl. 2):13-6.
9. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepati-lis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23(Suppl. 2) 17-21.
10. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone. Hepatology 1997;26:247.
11. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;! 13:1654-9.
12. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sei 1997;42:1681-7.
13. Findor JA, Daruich JR, Bruch Igartua E, Manero EF, Sordà F, Nakatsuno M, et al. Amantadine-HCL alone and associated with recombinant alpha interferon 2a during a short term therapy in chronic HCV infection. Hepatology 1997;26:217.
14. Fang JC, Hespenheide EE, Driscoll CJ, Caldvvell SH. Amantadine-HCL treatment of chronic hepatitis C. Hepatology 1997;26:217.
15. Roth WK, Lee J-H, Rüster B, Zeuzem S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-4.
16. Pawlotsky JM, Prescott L, Simmonds-P, Pellet C, Laurent-Puig P, Labonne C, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997;35:1734-9.
17. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995;45:348-53.
18. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(Suppl.l): 122-7.
19. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997:113:558-66.
20. Lindsay KL. Therapy of hepatitis C: Overview. Hepatology 1997;26(Suppl.l):71-7.
21. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection:prevalence, etiology, and management. Hepatology 1995:21:645-9.
22. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997:26:961-6.
23. Nicholson KG, Wiselka MJ. Amantadine for influenza A. BMJ 1991:302:425-6.
24. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, et al. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Hepatology 1997;25:445-8.
25. Zhao XX, Hua J, Smith T, Ferencz-Biro K, Liao MJ, Rashidbaigi A. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3. Hum Antibodies 1997;8:129-36.